Atlas Trials

Stage II-IIIB Non-small Cell Lung Carcinoma

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Stage II-IIIB Non-small Cell Lung Carcinoma

RecordFirmDate
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (NCT05526755)AstraZeneca2023-03-06

Track Stage II-IIIB Non-small Cell Lung Carcinoma automatically

Every clearance here is in the API, with alerts when new ones post.